Table 5. Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC).
| Author/ Year/ Country | Participating Institutions |
Study Period | Design | Level of Evidence | Number of CRC PC | Treatment strategy | |
|---|---|---|---|---|---|---|---|
| HIPEC group | Control group | ||||||
| Huang CQ/ 2014/ China [39] | 1 | 2004-2013 | retrospective | IIa | 62 (62/62) | CRS+HIPEC+SC with/without PIC 33 pts HIPEC: MMC (30 mg) + DDP (120 mg) for 90 min at 43.0±0.5°C using the Coliseum technique EPIC: DXL (75 mg/m2, on day 1, every 3 weeks) and CBP (at Calvert formula: area under the curve, AUC 5; on day 1, every 3 weeks) SC: FOLFOX or FOLFIRI |
CRS+ SC with/without PIC 29 pts SC: FOLFOX or FOLFIRI EPIC: DXL (75 mg/m2, on day 1, every 3 weeks) and CBP (at Calvert formula: AUC 5; on day 1, every 3 weeks) No HIPEC |
| Passot G/ 2014/ France [40] | 1 | 2005-2012 | retrospective | IIa | 82 (82/115) | Neoadjuvant SC+CRS+HIPEC 82 pts Neoadjuvant SC: 1. FOLFIRI with/without BEV or C225; 2. FOLFOX with/without BEV or C225; 3. Others regimens. HIPEC: L-OHP (360 mg/m2) for 30 min using the closed abdomen technique, not reported the perfusion temperature. No EPIC No SC |
Neoadjuvant SC + Surgery + SC 33 pts Neoadjuvant SC: 1. FOLFIRI with/without BEV or C225; 2. FOLFOX with/without BEV or C225; 3. Others regimens. No EPIC SC (uncertainty) |
| Verwaal VJ/ 2003 /Netherlands [12] | 1 | 1998-2001 | prospective | Ib | 87 (87/105) | CRS+HIPEC with/without SC 54 pts HIPEC: MMC (17.5 mg/m2) for 90 min between 42-44°C using the Coliseum technique No EPIC SC: 1. 5-FU (400 mg/m2) + LV (80 mg/m2); 2. FU + CPT-11 (350 mg/m2) |
Surgery and/or SC 51 pts SC: 1. 5-FU (400 mg/m2) + LV (80 mg/m2); 2. FU + CPT-11 (350 mg/m2) No EPIC No HIPEC |
Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;